Please try another search
For the three months ended 31 March 2020, Liminal BioSciences Inc revenues decreased 51% to C$1.1M. Net loss before extraordinary items decreased 4% to C$27.3M. Revenues reflect Plasma derived therapeutics segment decrease of 59% to C$901K, Small mole Cule segment decrease from C$31K to C$0K, United States segment decrease of 49% to C$731K, Canada segment decrease of 76% to C$205K.
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 1.1 | 4.9 | 5.29 | 8.75 |
Gross Profit | 0.42 | 2.14 | 2.25 | 4.87 |
Operating Income | -27.16 | -223 | -27.68 | -130.17 |
Net Income | -27.34 | -205.71 | -29.6 | -133.62 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 134.48 | 165.1 | 182.38 | 205.75 |
Total Liabilities | 55.98 | 62.91 | 68.53 | 64.29 |
Total Equity | 78.49 | 102.19 | 113.85 | 141.46 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -23.36 | -99.39 | -63.94 | -46.63 |
Cash From Investing Activities | 0.08 | 36.1 | -3.66 | -3.38 |
Cash From Financing Activities | -4.04 | 117.92 | 120.84 | 123.73 |
Net Change in Cash | -24.73 | 53.9 | 52.97 | 73.61 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review